{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:19:47Z","timestamp":1794557987097,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173763"],"award-info":[{"award-number":["82173763"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["91842305"],"award-info":[{"award-number":["91842305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81771686"],"award-info":[{"award-number":["81771686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ISF-NSFC Joint Scientific Research Program","award":["52161145501"],"award-info":[{"award-number":["52161145501"]}]},{"name":"Funds for Youth Interdisciplinary and Innovation Research Groups of Shandong University","award":["2020QNQT003"],"award-info":[{"award-number":["2020QNQT003"]}]},{"name":"the Fundamental Research Funds of Shandong Province","award":["ZR202206110012"],"award-info":[{"award-number":["ZR202206110012"]}]},{"name":"the Shandong Provincial Key Research and Development Program","award":["2021CXGC010515"],"award-info":[{"award-number":["2021CXGC010515"]}]},{"name":"the Shandong Provincial Key Research and Development Program","award":["2019JZZY011127"],"award-info":[{"award-number":["2019JZZY011127"]}]},{"name":"the Shandong Provincial Key Research and Development Program","award":["2019JZZY021013"],"award-info":[{"award-number":["2019JZZY021013"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2020MH260"],"award-info":[{"award-number":["ZR2020MH260"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Locoregional delivery of chimeric antigen receptor (CAR)-modified T (CAR-T) cells has emerged as a promising strategy for brain tumors. However, the complicated ex vivo cell manufacturing procedures and the rapid progression of the disease have limited its broader applications. Macrophages (M\u03a6s) exhibit unique effector functions and a high degree of infiltration within the solid tumor microenvironment (TME), especially in the brain, where M\u03a6s function as structural support, and the main immune effector cells of the CNS represent 5\u201312% of brain cells. Here, we report a synthetic universal DNA nanocarrier for in situ genetic editing of intratumoral M\u03a6s with an ErbB2-specific CAR to direct their phagocytic activity towards tumors and subsequently initiate a locoregional antitumor immune response. Specifically, we demonstrated that when delivered locoregionally, the RP-182 peptide, located in the shell of a nanoparticle, targeted M\u03a6s and reprogrammed M2-like tumor-associated macrophages (TAMs) to an antitumor M1-like phenotype. Subsequently, the CAR gene-laden DNA nanocomplex can be used to introduce ErbB2-targeted CAR, and the generated CAR-M\u03a6s then act as \u201cliving\u201d cures, thereby serially clearing the invasive tumor cells. Our work demonstrates a practical antitumor immunotherapy for brainstem gliomas (BSGs) that may be broadly applicable for patients suffering from other ErbB2-positive solid malignancies.<\/jats:p>","DOI":"10.1186\/s12951-023-01810-9","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T10:05:13Z","timestamp":1676887513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immunotherapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Lin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongdeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"1810_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11910-013-0346-3","volume":"13","author":"SA Grimm","year":"2013","unstructured":"Grimm SA, Chamberlain MC. Brainstem glioma: a review. Curr Neurol Neurosci Rep. 2013;13:346.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1810_CR2","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41467-020-16682-y","volume":"11","author":"LH Chen","year":"2020","unstructured":"Chen LH, Pan C, Diplas BH, Xu C, Hansen LJ, Wu Y, Chen X, Geng Y, Sun T, Sun Y, Zhang P, Wu Z, Zhang J, Li D, Zhang Y, Wu W, Wang Y, Li G, Yang J, Wang X, Xu C, Wang S, Waitkus MS, He Y, McLendon RE, Ashley DM, Yan H, Zhang L. The integrated genomic and epigenomic landscape of brainstem glioma. Nat Commun. 2020;11:3077.","journal-title":"Nat Commun"},{"key":"1810_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12964-021-00777-0","volume":"19","author":"X Xu","year":"2021","unstructured":"Xu X, Li L, Luo L, Shu L, Si X, Chen Z, Xia W, Huang J, Liu Y, Shao A, Ke Y. Opportunities and challenges of glioma organoids. Cell Commun Signal. 2021;19:102.","journal-title":"Cell Commun Signal"},{"key":"1810_CR4","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.neurol.2021.03.006","volume":"177","author":"T Dudoit","year":"2021","unstructured":"Dudoit T, Balossier A, Reyes-Botero G, Laigle-Donadey F, Emery E, Blond S, Carluer L, Lechapt-Zalcman E, Delattre JY, Guillamo JS. Adult brainstem glioma presenting with isolated persistent hemifacial spasm or facial nerve palsy. Rev Neurol. 2021;177:1276\u201382.","journal-title":"Rev Neurol"},{"key":"1810_CR5","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.2174\/0929867327666200806110206","volume":"28","author":"MG Perrone","year":"2021","unstructured":"Perrone MG, Ruggiero A, Centonze A, Carrieri A, Ferorelli S, Scilimati A. Diffuse intrinsic pontine glioma (DIPG): breakthrough and clinical perspective. Curr Med Chem. 2021;28:3287\u2013317.","journal-title":"Curr Med Chem"},{"key":"1810_CR6","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1158\/0008-5472.CAN-09-2503","volume":"70","author":"OJ Becher","year":"2010","unstructured":"Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, Hiner RL, Gall S, Huse JT, Jabado N, MacDonald TJ, Holland EC. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 2010;70:2548\u201357.","journal-title":"Cancer Res"},{"key":"1810_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/CCO.0000000000000577","volume":"31","author":"R Aziz-Bose","year":"2019","unstructured":"Aziz-Bose R, Monje M. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. Curr Opin Oncol. 2019;31:522\u201330.","journal-title":"Curr Opin Oncol"},{"key":"1810_CR8","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1002\/cncr.29920","volume":"122","author":"SC Eisele","year":"2016","unstructured":"Eisele SC, Reardon DA. Adult brainstem gliomas. Cancer. 2016;122:2799\u2013809.","journal-title":"Cancer"},{"key":"1810_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s00415-021-10725-0","volume":"269","author":"A Leibetseder","year":"2022","unstructured":"Leibetseder A, Leitner J, Mair MJ, Meckel S, Hainfellner JA, Aichholzer M, Widhalm G, Dieckmann K, Weis S, Furtner J, von Oertzen T, Preusser M, Pichler J, Berghoff AS. Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature. J Neurol. 2022;269:1574\u201390.","journal-title":"J Neurol"},{"key":"1810_CR10","first-page":"CD010439","volume":"2016","author":"X Hu","year":"2016","unstructured":"Hu X, Fang Y, Hui X, Jv Y, You C. Radiotherapy for diffuse brainstem glioma in children and young adults. Cochrane Database Syst Rev. 2016;2016:CD010439.","journal-title":"Cochrane Database Syst Rev"},{"key":"1810_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1810_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","volume":"26","author":"D Pettitt","year":"2018","unstructured":"Pettitt D, Arshad Z, Smith J, Stanic T, Hollander G, Brindley D, Cells CAR-T. A systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther. 2018;26:342\u201353.","journal-title":"Mol Ther"},{"key":"1810_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/jpm12050840","volume":"12","author":"S Damodharan","year":"2022","unstructured":"Damodharan S, Lara-Velazquez M, Williamsen BC, Helgager J, Dey M. Diffuse intrinsic pontine glioma: molecular landscape, evolving treatment strategies and emerging clinical trials. J Pers Med. 2022;12:840.","journal-title":"J Pers Med"},{"key":"1810_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42:126\u201335.","journal-title":"J Immunother"},{"key":"1810_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","volume":"9","author":"MM D'Aloia","year":"2018","unstructured":"D\u2019Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9:282.","journal-title":"Cell Death Dis"},{"key":"1810_CR16","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE. 2012;7:e50946.","journal-title":"PLoS ONE"},{"key":"1810_CR17","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"1810_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00281-013-0367-7","volume":"35","author":"SK Biswas","year":"2013","unstructured":"Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585\u2013600.","journal-title":"Semin Immunopathol"},{"key":"1810_CR19","doi-asserted-by":"publisher","first-page":"8874","DOI":"10.1158\/0008-5472.CAN-07-0177","volume":"67","author":"H Galarneau","year":"2007","unstructured":"Galarneau H, Villeneuve J, Gowing G, Julien JP, Vallieres L. Increased glioma growth in mice depleted of macrophages. Cancer Res. 2007;67:8874\u201381.","journal-title":"Cancer Res"},{"key":"1810_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119.","journal-title":"J Exp Clin Cancer Res"},{"key":"1810_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"1810_CR22","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305.","journal-title":"Front Immunol"},{"key":"1810_CR23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81:1201\u20138.","journal-title":"Cancer Res"},{"key":"1810_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:127.","journal-title":"Signal Transduct Target Ther"},{"key":"1810_CR25","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, Koo S, Kwon SP, Moon S, Jung M, Hong J, Go S, Song SY, Choi JH, Hyeon T, Oh YK, Park HH, Kim BS. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33:e2103258.","journal-title":"Adv Mater"},{"key":"1810_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L, Han M, Shi C, Li A, Sun P, Jiang X, Yang Z, Zhang S, Zhang J, Tang C, Liu Y, Zhang R, Xu F, Dong B, Li X, Liu M, Qiang B, Sun Y, Wei X, Li J, Hu Q, Jiang X. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14:1128.","journal-title":"Sci Transl Med"},{"key":"1810_CR27","first-page":"1549","volume":"42","author":"L Shen","year":"2019","unstructured":"Shen L, Li H, Bin S, Li P, Chen J, Gu H, Yuan W. The efficacy of third generation antiHER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells. Oncol Rep. 2019;42:1549\u201357.","journal-title":"Oncol Rep"},{"key":"1810_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094\u2013101.","journal-title":"JAMA Oncol"},{"key":"1810_CR29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389:1195\u2013205.","journal-title":"Lancet"},{"key":"1810_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"1810_CR31","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Kunkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27:1544\u201352.","journal-title":"Nat Med"},{"key":"1810_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62\u20138.","journal-title":"Science"},{"key":"1810_CR33","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/cells11121974","volume":"11","author":"DT Nguyen","year":"2022","unstructured":"Nguyen DT, Ogando-Rivas E, Liu R, Wang T, Rubin J, Jin L, Tao H, Sawyer WW, Mendez-Gomez HR, Cascio M, Mitchell DA, Huang J, Sawyer WG, Sayour EJ, Castillo P. CAR T cell locomotion in solid tumor microenvironment. Cells. 2022;11:1974.","journal-title":"Cells"},{"key":"1810_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","volume":"472","author":"W Wang","year":"2020","unstructured":"Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175\u201380.","journal-title":"Cancer Lett"},{"key":"1810_CR35","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.3390\/ijms22115899","volume":"22","author":"E Wrona","year":"2021","unstructured":"Wrona E, Borowiec M, Potemski P. CAR-NK cells in the treatment of solid tumors. Int J Mol Sci. 2021;22:5899.","journal-title":"Int J Mol Sci"},{"key":"1810_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","volume":"16","author":"S Tyagarajan","year":"2020","unstructured":"Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020;16:136\u201344.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1810_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","volume":"11","author":"M Daher","year":"2021","unstructured":"Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov. 2021;11:45\u201358.","journal-title":"Cancer Discov"},{"key":"1810_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.","journal-title":"J Hematol Oncol"},{"key":"1810_CR39","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1126\/scitranslmed.aax6337","volume":"12","author":"JM Jaynes","year":"2020","unstructured":"Jaynes JM, Sable R, Ronzetti M, Bautista W, Knotts Z, Abisoye-Ogunniyan A, Li D, Calvo R, Dashnyam M, Singh A, Guerin T, White J, Ravichandran S, Kumar P, Talsania K, Chen V, Ghebremedhin A, Karanam B, Bin Salam A, Amin R, Odzorig T, Aiken T, Nguyen V, Bian Y, Zarif JC, de Groot AE, Mehta M, Fan L, Hu X, Simeonov A, Pate N, Abu-Asab M, Ferrer M, Southall N, Ock CY, Zhao Y, Lopez H, Kozlov S, de Val N, Yates CC, Baljinnyam B, Marugan J, Rudloff U. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020;12:530.","journal-title":"Sci Transl Med"},{"key":"1810_CR40","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/nm.4415","volume":"23","author":"X Jin","year":"2017","unstructured":"Jin X, Kim LJY, Wu Q, Wallace LC, Prager BC, Sanvoranart T, Gimple RC, Wang X, Mack SC, Miller TE, Huang P, Valentim CL, Zhou QG, Barnholtz-Sloan JS, Bao S, Sloan AE, Rich JN. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat Med. 2017;23:1352\u201361.","journal-title":"Nat Med"},{"key":"1810_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41590-018-0292-y","volume":"20","author":"M Liu","year":"2019","unstructured":"Liu M, O\u2019Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated \u2018don\u2019t-eat-me\u2019 signal. Nat Immunol. 2019;20:265\u201375.","journal-title":"Nat Immunol"},{"key":"1810_CR42","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O\u2019Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"1810_CR43","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1039\/C3SC53550A","volume":"5","author":"A Leonidova","year":"2014","unstructured":"Leonidova A, Pierroz V, Rubbiani R, Lan YJ, Schmitz AG, Kaech A, Sigel RKO, Ferrari S, Gasser G. Photo-induced uncaging of a specific Re(I) organometallic complex in living cells. Chem Sci. 2014;5:4044\u201356.","journal-title":"Chem Sci"},{"key":"1810_CR44","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/nl400448n","volume":"13","author":"A Huefner","year":"2013","unstructured":"Huefner A, Kuan WL, Barker RA, Mahajan S. Intracellular SERS nanoprobes for distinction of different neuronal cell types. Nano Lett. 2013;13:2463\u201370.","journal-title":"Nano Lett"},{"key":"1810_CR45","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1021\/acsnano.7b07874","volume":"12","author":"YL Luo","year":"2018","unstructured":"Luo YL, Xu CF, Li HJ, Cao ZT, Liu J, Wang JL, Du XJ, Yang XZ, Gu Z, Wang J. Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles. ACS Nano. 2018;12:994\u20131005.","journal-title":"ACS Nano"},{"key":"1810_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/scitranslmed.aaw2672","volume":"12","author":"D Wang","year":"2020","unstructured":"Wang D, Starr R, Chang WC, Aguilar B, Alizadeh D, Wright SL, Yang X, Brito A, Sarkissian A, Ostberg JR, Li L, Shi Y, Gutova M, Aboody K, Badie B, Forman SJ, Barish ME, Brown CE. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020;12:533.","journal-title":"Sci Transl Med"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01810-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T11:12:24Z","timestamp":1676891544000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01810-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research involving human material have been performed in accordance with the Declaration of Helsinki and have been approved by Shandong First Medical University (No. 2020-272). Animal studies were approved by Laboratory Animal Ethical and Welfare Committee of Shandong University Cheeloo College of Medicine (No. 21074).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there is no conflict of interests regarding the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}